
Alzheimer’s Diagnosis Gets a Game-Changing Makeover: It Starts with Your Blood
FDA-approved blood tests transform Alzheimer’s diagnosis by detecting pTau217 and amyloid proteins in plasma with 91% accuracy, bypassing costly PET scans or spinal taps. For symptomatic patients over 55, results arrive in days via routine draws, enabling early intervention amid 7M U.S. cases projected to double by 2050.




